A new method to enhance T cell modification using engineered viruses
Official title: A Novel Vector Platform to Actualize T Cell Modification In Vivo
Funded at Washington University · NIH-10663022 · Data updated 2026-11-12
This study is exploring a new way to deliver gene editing tools directly into T cells using specially modified viruses, which could lead to better cancer treatments that are more precise and effective for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | August 4, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $427,625 |
| NIH project number | 1R21EB033459-01A1 |
| Project ID | NIH-10663022 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers that may benefit from enhanced T cell therapies.
✕Less likely to help
Patients with non-malignant conditions or those not eligible for T cell modification therapies may not receive benefits from this research.
What this research studies
This research focuses on developing a novel vector platform that combines adenoviruses and adeno-associated viruses to improve the delivery of gene editing tools directly into T cells. By using advanced techniques to modify the virus capsids, the researchers aim to enhance the targeting efficiency of these viruses to specific tissues, such as the liver. The approach involves using engineered viral components to facilitate better gene editing outcomes, potentially leading to more effective immunotherapy treatments for cancer. Patients may benefit from this innovative method that aims to improve the precision and effectiveness of T cell modifications.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapies for cancer patients by improving T cell modification techniques.
How similar studies have gone: Other research has shown promise in using engineered viral vectors for gene delivery, indicating that this approach could be a significant advancement in the field.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Curiel, David Terry — Washington University
- Study coordinator: Curiel, David Terry
Related research
Other NIH-funded projects on the same topics.
-
Using MRI to measure brain oxygen levels as an early sign of small vessel disease in the brain
This study is looking at how measuring oxygen levels in the brain with MRI can help spot early signs of small vessel disease, which is linked to memory problems and dementia, especially Alzheimer's, so if you're at risk due to age or high blood pressure, you might be able to participate in MRI scans to learn more about
-
Advanced Methods & Modeling for Better Patient Care
A funding opportunity focused on developing new modeling methods to improve health care for patients through better data use and analytics.
-
Advanced methods and modeling for health research at Washington University
A health research grant at Washington University funds new modeling methods to support future patient-focused studies.
-
Center for Research in Emerging Infectious Diseases: Epidemiology, Surveillance and Pathogenesis
A NIH program will study and monitor emerging viruses from the Midwest U.S. and three Asian sites to understand how they spread and affect people.
-
How Poverty and the Environment Affect Heart Disease in Haiti and Beyond
This grant studies how poverty-related factors like food insecurity, stress, and pollution contribute to heart disease and aims to follow a large group of adults to better understand and prevent the disease.
-
Wearable tech to track blood loss during childbirth
A wearable device monitors cardiovascular signals to detect postpartum hemorrhage early so clinicians can act quickly to protect mothers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.